Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Title:Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Volume: 14 Issue: 5

Author(s): Vasilios G. Athyros, Niki Katsiki and Nikolaos Tentolouris

Affiliation:

Keywords: Glucagon-like-peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors, type 2 diabetes mellitus, cardiovascular disease, heart failure.

Cite this article as:

Athyros G. Vasilios, Katsiki Niki and Tentolouris Nikolaos, Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial), Current Vascular Pharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570161114666160909161537